Scheme for Strengthening of Medical Device Industry (SMDI) - Marginal Investment Scheme for Reducing Import Dependence (MISRID)
Department of Pharmaceuticals · Central government
The SMDI capital subsidy scheme funds domestic manufacturing of key medical device components and raw materials to cut import reliance.
Closed. Applications closed on 24 July 2026. The details below describe the most recent cycle.
Key facts
- Subsidy amount
- Up to ₹10,00,00,000
- Instrument
- Subsidy
- Deadline
- 24 July 2026
- Disbursement
- Reimbursed after spend
About this scheme
The Scheme for Strengthening of Medical Device Industry (SMDI), run by the Department of Pharmaceuticals under the Ministry of Chemicals & Fertilizers, Government of India, targets greater self-reliance in the medical device sector. Within it, the Marginal Investment Scheme for Reducing Import Dependence (MISRID) focuses on localising the production of critical components, raw materials, and accessories used in medical device manufacturing, including in-vitro diagnostics (IVDs). The sector has long depended on imports for these inputs, creating supply chain vulnerabilities and raising production expenses. The scheme offers financial incentives to domestic firms to manufacture such items.
The goal is to build a self-sustaining indigenous manufacturing base for medical devices, improving the country's ability to produce quality, affordable equipment. By encouraging local output of components such as sensors, embedded systems, optical filters, electrodes, and medical-grade materials, SMDI-MISRID seeks to drive innovation, generate jobs, and position India as a global manufacturing centre for medical devices. This effort supports the 'Make in India' initiative and strengthens public health by securing domestic availability of essential devices, particularly during global health emergencies.
Who can apply
- Eligible business forms
- Private limited company, Limited liability partnership, One person company, Partnership firm, Sole proprietorship
- Udyam registration
- Not specified
- MSME registration
- Not specified
- DPIIT startup recognition
- Not specified
- GST registration
- Not specified
- Where the business may be based
- Not restricted
- Open to Central/State Government Organisations, Companies/LLPs, and Special Purpose Vehicles (SPVs) registered under the Companies Act or Societies Registration Act in India. - Medical device/in-vitro diagnostic manufacturers with existing facilities, or those intending to produce key components, input materials, or accessories. - Manufacturers of critical raw materials (e.g., polymer, glass, metal, textile, paper for medical grade use). - Importers who intend to shift to manufacturing any medical device or IVD on the GTE list.
How to apply
1. Go to the official SMDI portal at https://smdi.lsssdc.in/. 2. Open the application section for the Marginal Investment Scheme for Reducing Import Dependence (MISRID). 3. Register your organisation and complete the online application form with all required particulars. 4. Attach the supporting documents, which generally comprise company registration certificates, financial statements, detailed project proposals, investment plans, and technical specifications of the components or materials intended for manufacture. 5. Submit your application by the deadline of July 24, 2026. 6. Track your application status on the portal and address any clarifications raised by the scheme administrators. 7. Candidates shortlisted will move to the evaluation phase, which includes a technical review and committee appraisals.
How applications are assessed
The evaluation for SMDI-MISRID follows a staged procedure. Initially, a Project Management Agency (PMA) checks each application for completeness and conformity with the basic eligibility requirements. A Technical Committee then assesses the technical viability, novelty, and strategic relevance of the proposed manufacturing projects. In the final stage, the Scheme Steering Committee grants the necessary approval, confirming that the chosen projects support the broader aims of bolstering the medical device sector and lowering reliance on imports.
Frequently asked questions
What is the primary objective of the MISRID scheme?
The scheme aims to boost domestic manufacturing of critical inputs—such as components, raw materials, and accessories—for medical devices, including in-vitro diagnostic devices, thereby cutting India's reliance on imported supplies.
Who is eligible to apply for this scheme?
Eligible applicants are Central or State Government organisations, companies or LLPs registered in India, and Special Purpose Vehicles (SPVs) registered under the Companies Act or Societies Registration Act. This includes manufacturers of medical devices, IVDs, critical raw materials, and importers planning to move into manufacturing.
What is the maximum subsidy amount I can receive?
The maximum capital subsidy is ₹10 Crore, disbursed on a reimbursement basis. The applicable percentage—20%, 15%, or 10%—is determined by the company's annual turnover, with smaller firms receiving a higher subsidy rate on their investment.
What kind of activities are eligible for this subsidy?
Eligible activities cover the manufacture of key components, raw materials, and accessories for medical devices and IVDs, including sensors, embedded systems, optical filters, electrodes, antigens/antibodies, polymer tubing, metal tubing, and medical-grade packaging materials.
Is co-financing required for this scheme?
Yes, the incentive is a capital subsidy paid on reimbursement, so you must fund the initial investment yourself and will receive a percentage of it back afterwards. This means the scheme requires co-financing from your side.
What is the project completion timeline?
Projects approved under the scheme must be completed within two years of final approval, with a possible one-year extension under specific circumstances.
Sectors
- Health Pharma Biotech
- Medical Devices
- Healthcare Manufacturing
- Import Substitution
- Capital Subsidy
- Invitro Diagnostics
- Pharmaceuticals
Details last verified on 3 August 2026. Source: the issuer's published information.